Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
August 04, 2021 21:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference
August 04, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
July 29, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio Announces Key Executive Appointments
July 19, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central...
Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio
June 01, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
Passage Bio to Participate in Upcoming June Investor Conferences
May 26, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting
May 11, 2021 06:30 ET
|
Passage Bio
Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy...
Passage Bio to Host Virtual R&D Event on May 17
May 10, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central...
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 05, 2021 07:00 ET
|
Passage Bio
Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21Received multiple regulatory clearances for clinical...